Image may be NSFW.
Clik here to view.
Clik here to view.
Rodman starts BioBlast Pharma at buy
Rodman & Renshaw has initiated coverage of BioBlast Pharma (NASDAQ:ORPN) with a “buy” rating and 12-month price target of $25. The stock closed at $3.24 on Wednesday. BioBlast is focused on...
View Article
More Pages to Explore .....
